Descrizione del progetto
Una terapia iniettabile, mirata e attivata dalla luce per l’iperinsulinismo congenito
Le cellule dell’organismo sono «alimentate» dal glucosio prodotto dalla digestione dei carboidrati. Quando i livelli di glucosio nel sangue aumentano, le cellule beta del pancreas rilasciano insulina che consente all’organismo di assorbire il glucosio. Troppo o troppo poco glucosio in circolazione può causare problemi. L’iperinsulinismo congenito è una condizione dei neonati e dei bambini causata da una sovrapproduzione di insulina, con conseguenti livelli di glucosio nel sangue pericolosamente bassi e danni cerebrali da ipoglicemia. Attualmente non è disponibile alcuna terapia che non comporti gravi effetti collaterali, continui problemi di salute e un enorme onere economico. Il progetto LightCure, finanziato dall’UE, intende dimostrare che la sua terapia fotodinamica mirata iniettabile può uccidere le cellule beta iperfunzionanti in modo sicuro ed efficace, così da consentire ai bambini e alle loro famiglie di condurre una vita normale.
Obiettivo
Congenital hyperinsulinism (CHI) is a group of rare diseases of newborns and infants with functionally defective nonneoplastic beta-cells that cause hypoglycemia and severe morbidity through oversecretion of insulin. CHI is a major cause of hypoglycemic brain injury with intellectual disability, epilepsy and cerebral palsy. As no registered causal therapy exists, management of CHI aims at increasing blood glucose levels causing severe side effects in all patients while life-threatening frequent hypoglycaemias remain. Removal of hyperfunctioning beta cells by pancreatectomy leads to insulin dependent diabetes mellitus (IDDM) and maldigestion of food, changing one disease for another with severe secondary morbidity. Management of CHI is choosing between evils and symptomatic management is partially effective in only some sub-types. CHI also represents a major burden for families, because of disability but also as a result of continuous monitoring and correction of glucose levels for many years, requiring permanent alertness. Health problems and economic decline occur in most parents. A normal life is not feasible for families with babies with CHI. LightCure consortium partners have demonstrated the feasibility of selectively targeting beta cells using exendin 4 (EX) labelled with a photosensitizer (700DX) specifically binding to beta cells. This photosensitizer can be activated by light of a certain wavelength and will produce radical oxygen species leading to cell damage, a principle called targeted photodynamic therapy (tPDT). In this project we will build on existing cutting-edge technology exclusively available to the consortium partners and perform human proof of concept studies demonstrating safety and efficacy of tPDT with EX700DX. We will deliver the proof-of-concept that after injection of EX700DX, minimally invasive tPDT leads to normalization of blood glucose levels avoiding morbidity, enabling a normal life for babies with CHI and their families.
Campo scientifico
Parole chiave
Programma(i)
Argomento(i)
Invito a presentare proposte
HORIZON-HLTH-2022-DISEASE-06-two-stage
Vedi altri progetti per questo bandoMeccanismo di finanziamento
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinatore
6525 GA Nijmegen
Paesi Bassi